Mr. Craig Schneider reports

INMED PHARMACEUTICALS APPOINTS DR. ABO MOHAMMED AS CHIEF MEDICAL OFFICER

InMed Pharmaceuticals Inc. has appointed former associate medical director of GW Pharmaceuticals, Dr. Abo Mohammed, MD, DPM, MFPM, as chief medical officer, effective immediately. Dr. Mohammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, research and development, and commercialization of these specialty drugs.

As CMO, Dr. Mohammed will join InMed's executive management team, and will be directly involved in developing the clinical trial strategy for InMed's lead candidates and product development strategy for the company's pipeline of cannabinoid-based therapies, including its two clinical-stage programs, CTI-085 and CTI-091, and the recently initiated program for epidermolysis bullosa simplex (EBS), INM-750.

"Our recent progress and anticipated advancement of our lead drug candidates have made the creation of the CMO position a corporate priority," commented Craig Schneider, chief executive officer of InMed Pharmaceuticals. "There are very few individuals worldwide who have Dr. Mohammed's level of expertise and direct experience in cannabinoid drug development. We are very fortunate to have been able to attract such a qualified executive to the InMed team."

Dr. Sazzad Hossain, chief scientific officer, added, "Dr. Mohammed's expertise in regulatory affairs, clinical development and marketing in cannabinoid-based therapies is expected to add immediate value to InMed as we seek to successfully advance our cannabinoid-based therapies along the clinical and regulatory pathway."

Dr. Mohammed commented: "Joining InMed at this transformative stage, as the company prepares for clinical development of its lead programs, is the opportunity I had been seeking to continue my passion for bringing cannabinoid therapies to the market. I look forward to leveraging my expertise in support of InMed's exciting drug candidates."

Prior to joining InMed Pharmaceuticals, Dr. Mohammed served as associate medical director at GW Pharmaceuticals, a United Kingdom-based pharmaceutical company specializing in the development of cannabinoid-based prescription medicines. In this role, and others at GW Pharmaceuticals, Dr. Mohammed was involved in the advanced delivery of core clinical research, and was involved in key decision making regarding research and development, and product commercialization. He played a leading role in GW Pharmaceuticals' pharma-covigilance team, where his responsibilities included handling of the company's drug safety data from both clinical trials and postmarketing sources, and general management of safety signals including investigations, reviews and reporting. He is also a consultant to the Nigerian regulatory authority (National Agency for Food and Drug Administration and Control) in the areas of pharma-covigilance, postmarketing surveillance and clinical trials.

Prior to joining GW Pharmaceuticals, Dr. Mohammed was with PPD (Pharmaceutical Product Development), a leading global contract research organization providing drug discovery, development, life cycle management and laboratory services. Dr. Mohammed also served as CMO/clinical director in various public health care establishments in Africa from 1996 to November, 2010.

Dr. Mohammed received his MD at Ahmadu Bello University, Zaria, Nigeria, followed by an MSc in orthopedics at University College London. Dr. Mohammed achieved a DipPharMed in pharmaceutical medicine at the University of Wales in Cardiff. He is a member of the faculty of pharmaceutical medicine at the Royal College of Physicians of England, the British Association of Pharmaceutical Physicians and the International Society for Pharma-covigilance.

We seek Safe Harbor.